Pacific Therapeutics Ltd. to Present at BioFinance 2010

Vancouver, BC April 7, 2010 Pacific Therapeutics Ltd. ("Pacific") today announced that thatMr. Doug Unwin, President and Chief Executive Officer, will present an overview of the Company at the BioFinance 2010 Conference, which is taking place this week in Toronto. Mr. Unwin will be speaking this afternoon at 2:00pm EDT. Mr. Unwin will discuss advances made in our pipeline and technologies.

About the BioFinance 2010
BioFinance 2010 is the leading investor conference in Canada for the life sciences industry. This event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences sector.

About Pacific Therapeutics
Pacific Therapeutics Ltd. (Pacific) is a Development stage Specialty Pharmaceutical Company, poised to begin Clinical Trials. The company is focused on developing late stage clinical therapies and in licensed novel compounds for Pulmonary Fibrosis indications. Pacific's lead compound PTL-202 is a combination of already approved drugs with a well established safety profile. The company will take this therapy into a Clinical trial in Pulmonary Fibrosis. PTL will seek a partner for further clinical development after completing Phase 2 proof of principal studies. Pulmonary Fibrosis represents a market opportunity in excess of $2.0 billion.

Contact:

Doug Unwin
President & CEO
Pacific Therapeutics Ltd.
Phone: (604) 738-1049
Email: unwin@pacifictherapeutics.com